Update on the development of HIV entry inhibitors (Q58388992)

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Anticancer and antiviral sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

New anti-HIV agents and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

New advances in HIV entry inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Potential new therapies for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Immunological approaches for HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Signals and receptors involved in recruitment of inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Structure, function, and inhibition of chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Protein design of an HIV-1 entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Molecular targets of anti-HIV-1 triterpenes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Blocking the docking of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

HIV infection is blocked in vitro by recombinant soluble CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A new classification for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Combinatorial synthesis of CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Cellular pharmacology studies of shikonin derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The therapeutic potential of CXCR4 antagonists in the treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Safe use of the CXCR4 inhibitor ALX40-4C in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Short constrained peptides that inhibit HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

HIV-1 inhibition by a peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

HIV fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

21 January 2018

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479

Small molecule antagonists of chemokine receptors as emerging anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17469600.2.5.479